Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kamada Ltd. stock logo
KMDA
Kamada
$6.87
-0.3%
$6.57
$4.74
$9.16
$394.89M0.9490,762 shs28,119 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.30
$6.65
$381.02M0.93.36 million shsN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$7.88
-0.1%
$2.67
$1.31
$7.95
$367.78M1.9652,735 shs849,129 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.12
$0.09
$0.17
$95.35M1.034.45 million shs790,936 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kamada Ltd. stock logo
KMDA
Kamada
-0.29%+1.93%+4.09%-0.29%+32.37%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+30.36%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-0.13%0.00%+310.42%+225.62%+165.32%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%-10.06%-44.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kamada Ltd. stock logo
KMDA
Kamada
4.1819 of 5 stars
3.45.00.00.02.81.73.1
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
1.9753 of 5 stars
3.10.00.04.70.01.70.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.1593 of 5 stars
4.03.00.00.02.32.50.6
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kamada Ltd. stock logo
KMDA
Kamada
2.75
Moderate Buy$14.67113.49% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8037.06% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ZOM, KMDA, RVNC, and VIGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$11.00 ➝ $8.00
5/27/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$14.00 ➝ $8.00
5/23/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Neutral$8.00
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.00
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kamada Ltd. stock logo
KMDA
Kamada
$167.24M2.36$0.38 per share17.90$4.25 per share1.62
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$3.24 per shareN/A
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M0.00N/AN/A$0.24 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kamada Ltd. stock logo
KMDA
Kamada
$8.28M$0.2924.5421.470.979.92%6.30%4.49%8/13/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/A

Latest ZOM, KMDA, RVNC, and VIGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/7/2025Q1 2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.53-$0.49+$0.04-$0.49N/AN/A
3/13/2025Q4 2024
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.49-$0.57-$0.08-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A

Latest ZOM, KMDA, RVNC, and VIGL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/5/2025
Kamada Ltd. stock logo
KMDA
Kamada
--$0.203/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kamada Ltd. stock logo
KMDA
Kamada
N/A
4.84
2.73
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
3.72
3.72
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
10.82
10.15

Institutional Ownership

CompanyInstitutional Ownership
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
Zomedica Corp. stock logo
ZOM
Zomedica
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.48 million36.73 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4046.67 million27.38 millionNot Optionable
Zomedica Corp. stock logo
ZOM
Zomedica
50979.95 million938.89 millionNot Optionable

Recent News About These Companies

15 Cheapest Stocks Insiders Are Buying In March
Q4 2024 Zomedica Corp Earnings Call
Zomedica (ZOMDF) Gets a Buy from Noble Financial
Zomedica Corp.
Zomedica Corp (ZOM) Stock Trading Recap

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kamada stock logo

Kamada NASDAQ:KMDA

$6.87 -0.02 (-0.29%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$6.89 +0.02 (+0.29%)
As of 05/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)
As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$7.88 -0.01 (-0.13%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$7.86 -0.01 (-0.19%)
As of 05/29/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Zomedica stock logo

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.